glp-1 research studies Pediatric Implications and Opportunities for GLP‐1 GLP-1-based therapies for diabetes, obesity

Because of their different protective actions, these two drug classes may have additive effects that help preserve beta cells

It is worth noting that clinical trial data may differ from real-world experience

In a separate enforcement action, DMHC fined Blue Shield of California Promise Health Plan for failing to provide clear, accurate, and timely written explanations for claim denials, reinforcing concerns about transparency and consistency in coverage determinations

The foundational characterization appeared in European Journal of Endocrinology in 1998, reporting selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a) without significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses 200-fold above the GH-releasing ED50 in preclinical models